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EDITORIAL
Polycystin: From structure to function
Autosomal dominant polycystic kidney disease ceptor tyrosine kinase inhibitors failed to block cAMP-
(ADPKD) is a multisystem disease characterized by the mediated proliferation of tubular cells from ADPKD
progressive development of numerous fluid-filled cysts patients. These studies indicate that cAMP agonists stim-
in the kidney, leading to chronic renal failure. Predomi- ulate PKA-mediated activation of ERK, at a locus distal
nant tubular epithelial cell abnormalities associated with to receptor tyrosine kinase in ADPKD cells, but not in
ADPKD include abnormal maturation, excessive prolif- NHK cells.
eration, and fluid secretion. Since polycystin 1 and poly- The basis for this fundamental difference in the prolif-
cystin 2 have been cloned, more recent studies have erative response of ADPKD and NHK cells to cAMP
focused on defining the mechanism through which struc- agonists, and how this difference may be related to struc-
tural alterations in these genes give rise to the tubular tural alterations in the polycystin molecules raises a num-
epithelial cell abnormalities characteristic of ADPKD. ber of questions that need to be addressed by further
Polycystin 1 has 9 to 11 transmembrane domains, a large study:
amino terminal extracellular tail that appears to be in- (1) Is the cAMP-PKA pathway abnormally activated
volved in cell-cell and cell-matrix interactions, and a in ADPKD? To demonstrate that the proliferative re-
cytoplasmic carboxy terminus that contains a number of sponse of ADPKD cells to cAMP agonists is relevant to
motifs that may interact with the cytoskeleton and play our understanding of the pathophysiology of polycystic
an important role in intracellular signaling [1]. In vitro kidney disease, it will be necessary to show that the
expression studies have shown that the cytoplasmic do- cAMP-PKA pathway is indeed activated. There is some
main of polycystin 1 contains sites that are phosphory- indirect evidence in support of this activation. In the
lated by protein kinase A and c-src [2] and may be in- murine pcy/pcy model of PKD, cystogenesis is associated
volved in the protein kinase C a dependent and c-Jun with a progressive increase in renal cAMP content [5].
N-terminal kinase dependent activation of transcription Cysts from human ADPKD patients contain micromolar
factors, including AP-1 [3]. concentrations of ATP and metabolites of ATP, presum-
Despite these advances, the mechanisms underlying ably released from cyst lining epithelial cells [6]. In the-
excessive tubular epithelial cell proliferation in ADPKD ory, this concentration of ATP is sufficient to activate renal
have not been defined. In this issue of Kidney Interna- epithelial cell purinergic receptors, increasing secretion of
tional, Yamaguchi and colleagues provide evidence that fluid into the cyst lumen. However, further studies are
cyclic AMP (cAMP) may play a critical role as a second needed to determine whether intracellular activation of
messenger in a signaling pathway leading to tubular epi- the cAMP-PKA pathway occurs in ADPKD.
thelial cell proliferation and fluid secretion in ADPKD (2) If the cAMP-PKA pathway is indeed activated in
[4]. In tubular epithelial cells derived from normal hu- ADPKD, how does this relate to structural abnormalities
man kidney (NHK), agonists of the cAMP signaling sys- in the polycystin 1 and/or polycystin 2 gene products?
tem block basal and growth factor-mediated activation of Cystogenic epithelium in ADPKD is often described as
the extracellular signal-regulated protein kinase (ERK) having a “fetal-like” phenotype, characterized by persis-
pathway and inhibit proliferation. In contrast, Yama- tent expression of genes expressed during embryogene-
guchi et al report that agonists of the cAMP signaling sis, by an increased rate of proliferation, and by abnormal
system stimulate proliferation of tubular epithelial cells polarity of ion transporters and growth factor receptors.
derived from patients with ADPKD. The stimulatory ef- It is certainly possible that structural abnormalities in
fect of cAMP on proliferation of ADPKD cells was associ- the polycystin molecules give rise to a wide variety of
ated with activation of the ERK-pathway. Both protein defects in cell-cell and/or cell-matrix interactions during
kinase A (PKA) inhibitors and MEK (mitogen-activated, embryogenesis, and may thereby alter the pattern of
ERK-activating kinase) inhibitors blocked the prolifera- gene expression associated with normal tubular epithe-
tive response of ADPKD cells to cAMP. However, re- lial cell growth and development. The precise mechanism
by which these developmental alterations lead to in-
creased cAMP-PKA signaling needs to be defined. An-Key words: ADPKD, cAMP, transcription factors, normal human
kidney. other possibility is that structural defects in and/or aber-
rant expression of polycystin in tubular epithelial cellsÓ 2000 by the International Society of Nephrology
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gives rise to alterations in intracellular cAMP metabo- The studies by Yamaguchi et al provide indirect evi-
dence that polycystin may play a key role in the organiza-lism in ADPKD. Intracellular cyclic nucleotide levels
are largely regulated through catabolic pathways medi- tion and integration of signals that regulate a variety of
processes, including proliferation and secretion. Studiesated by a large family of phosphodiesterases (PDEs) [7].
Even partial inhibition of PDEs may give rise to a many- to determine whether components of the cAMP-PKA
signaling pathway directly interact with polycystin andfold increase in cAMP-PKA signaling. Recent studies,
using PDE isoform-specific inhibitors, have demonstrated to determine how these interactions may be altered may
provide important insights into the pathophysiology ofthat mesangial cells contain functionally compartmental-
ized pools of cAMP that regulate disparate cellular func- ADPKD. These studies may provide the basis for tar-
geting the cAMP-PKA pathway through “signal trans-tions, including mitogenesis and reactive oxygen species
generation. Activation of the cAMP-PKA pathway in duction pharmacotherapy” to inhibit tubular epithelial
cell mitogenesis and secretion, thereby retarding the rateADPKD may therefore be secondary to a deficiency
in PDE production and/or compartmentalization. Even of cystogenesis in patients with ADPKD.
though it may be possible to relate deficiencies in PDE
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